Evidence map›Paper›PMID 31213659›Full record

ArticleBritish journal of cancer2019

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.

Frank Qian, Matti A Rookus, Goska Leslie, Harvey A Risch, Mark H Greene, Cora M Aalfs, Muriel A Adank, Julian Adlard, Bjarni A Agnarsson, Munaza Ahmed and 133 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Genetics of early growth traits.Human molecular genetics · 2020
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

143 authors at 20 institutions in 24 countries.

Frank QianDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Matti A RookusDepartment of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Goska LeslieCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Harvey A RischChronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Mark H GreeneClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Cora M AalfsDepartment of Clinical Genetics, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.
Muriel A AdankFamily Cancer Clinic, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Julian AdlardYorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
Bjarni A AgnarssonDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Munaza AhmedNorth East Thames Regional Genetics Service, Great Ormond Street Hospital, London, UK.
Kristiina AittomäkiDepartment of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Norbert ArnoldDepartment of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
Banu K ArunDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Margreet G E M AusemsDivision Laboratories, Pharmacy and Biomedical Genetics, Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Jacopo AzzolliniUnit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Daniel BarrowdaleCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Julian BarwellLeicestershire Clinical Genetics Service, University Hospitals of Leicester NHS Trust, Leicester, UK.
Javier BenitezHuman Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Katarzyna BiałkowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Valérie BonadonaUnité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France.
Julika BordeCenter for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany.
Ake BorgDepartment of Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Angela R BradburyDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Joan BrunetGenetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut d'Investigació Biomèdica de Girona), Catalan Institute of Oncology, CIBERONC, Girona, Spain.
Saundra S BuysDepartment of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Trinidad CaldésMedical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Maria A CaligoSection of Molecular Genetics, Dept. of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.
Ian CampbellPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Jonathan CarterDepartment of Gynaecological Oncology, Chris O'Brien Lifehouse and The University of Sydney, Camperdown, NSW, Australia.
Jocelyne ChiquetteCRCHU de Québec- oncologie, Centre des maladies du sein Deschênes-Fabia, Hôpital du Saint-Sacrement, Québec, QC, Canada.
Wendy K ChungDepartments of Pediatrics and Medicine, Columbia University, New York, NY, USA.
Kathleen B M ClaesCentre for Medical Genetics, Ghent University, Gent, Belgium.
J Margriet ColléeDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marie-Agnès Collonge-RameService de Génétique, CHU de Besançon, Besançon, France.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mary B DalyDepartment of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Capucine DelnatteUnité d'Oncogénétique, ICO-Centre René Gauducheau, Saint Herblain, France.
Orland DiezOncogenetics Group, Clinical and Molecular Genetics Area, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Susan M DomchekDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Cecilia M DorflingDepartment of Genetics, University of Pretoria, Arcadia, South Africa.
Jacqueline EasonNottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Ros EelesOncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
D Gareth EvansDivision of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Laurence FaivreUnité d'oncogénétique, Centre de Lutte Contre le Cancer, Centre Georges-François Leclerc, Dijon, France.
Lidia FeliubadalóMolecular Diagnostic Unit, Hereditary Cancer Program, ICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC, Barcelona, Spain.
Lenka ForetovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Eitan FriedmanThe Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel.
Debra FrostCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Patricia A GanzSchools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Centre, UCLA, Los Angeles, CA, USA.
Judy GarberCancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA.
Vanesa Garcia-BarberanDepartment of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Andrea GehrigCentre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Würzburg, Germany.
Gord GlendonFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS, USA.
Encarna B Gómez GarciaDepartment of Clinical Genetics and GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Ute HamannMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jan HaukeUnité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France.
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Peter J HulickCenter for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Evgeny N ImyanitovN.N. Petrov Institute of Oncology, St. Petersburg, Russia.
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Louise IzattClinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Anna JakubowskaBiomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
Ramunas JanaviciusHematology, oncology and transfusion medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.
Esther M JohnDepartment of Medicine, Division of Oncology, and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Carolien M KetsDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Yael LaitmanThe Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel.
Conxi LázaroMolecular Diagnostic Unit, Hereditary Cancer Program, ICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC, Barcelona, Spain.
Dominique LerouxDépartement de Génétique, CHU de Grenoble, Grenoble, France.
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Fabienne LesueurGenetic Epidemiology of Cancer team, Inserm U900, Paris, France.
Jennifer T LoudClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jan LubińskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Alicja ŁukomskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Lesley McGuffogCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Noura MebiroukGenetic Epidemiology of Cancer team, Inserm U900, Paris, France.
Hanne E J Meijers-HeijboerDepartment of Clinical Genetics, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands.
Alfons MeindlDepartment of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany.
Austin MillerNRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
Marco MontagnaImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Thea M MooijDepartment of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Emmanuelle Mouret-FourmeService de Génétique, Institut Curie, Paris, France.
Katherine L NathansonDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Bita NehorayClinical Cancer Genomics, City of Hope, Duarte, CA, USA.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Finn C NielsenCenter for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Kenneth OffitClinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Edith OlahDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Kai-Ren OngWest Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Birmingham, UK.
Jan C OosterwijkDepartment of Genetics, University Medical Center Groningen, University Groningen, Groningen, The Netherlands.
Laura OttiniDepartment of Molecular Medicine, University La Sapienza, Rome, Italy.
Michael T ParsonsDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Paolo PeterlongoGenome Diagnostics Program, IFOM - the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy.
Georg PfeilerDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Nisha PradhanClinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Susan J RamusSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Johanna RantalaClinical Genetics, Karolinska Institutet, Stockholm, Sweden.
Gad RennertClalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Mark RobsonClinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Gustavo C RodriguezDivision of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, IL, USA.
Ritu SalaniWexner Medical Center, The Ohio State University, Columbus, OH, USA.
Maren T ScheunerCancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA, USA.
Rita K SchmutzlerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Payal D ShahDepartment of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Lucy E SideWessex Clinical Genetics Service, University Hospitals Southampton NHS Trust, Southampton, UK.
Jacques SimardGenomics Center, Centre Hospitalier Universitaire de Québec - Université Laval, Research Center, Québec City, QC, Canada.
Christian F SingerDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-1294-0027
Doris SteinemannInstitute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
Dominique Stoppa-LyonnetService de Génétique, Institut Curie, Paris, France.
Yen Yen TanDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Mary Beth TerryDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Mads ThomassenDepartment of Clinical Genetics, Odense University Hospital, Odence C, Denmark.
Marc TischkowitzProgram in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, Canada.
Silvia TognazzoImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Amanda E TolandDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-0271-1792
Nadine TungDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Christi J van AsperenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Klaartje van EngelenDepartment of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Elizabeth J van RensburgDepartment of Genetics, University of Pretoria, Arcadia, South Africa.
Laurence Venat-BouvetDepartment of Medical Oncology, CHU Dupuytren, Limoges, France.
Jeroen VierstraeteCentre for Medical Genetics, Ghent University, Gent, Belgium.
Gabriel WagnerDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Lisa WalkerOxford Regional Genetics Service, Churchill Hospital, Oxford, UK.
Jeffrey N WeitzelClinical Cancer Genomics, City of Hope, Duarte, CA, USA.
Drakoulis YannoukakosMolecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
KConFab Investigators
HEBON Investigators
GEMO Study Collaborators
EMBRACE Collaborators
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
David E GoldgarDepartment of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Olufunmilayo I OlopadeCenter for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA.
Georgia Chenevix-TrenchDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Timothy R RebbeckHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Dezheng HuoCenter for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA. dhuo@health.bsd.uchicago.edu.
CIMBA
University of Cambridge · GBComprehensive Cancer Center Vienna · ATMemorial Sloan Kettering Cancer Center · USMount Sinai Hospital · CANorthShore University HealthSystem · USUniversity of Cologne · DECedars-Sinai Medical Center · USHuntsman Cancer Institute · USQIMR Berghofer Medical Research Institute · AUSheba Medical Center · ILUniversity of Helsinki · FIUniversity of Pennsylvania · USBeth Israel Deaconess Medical Center · USCentre Hospitalier Universitaire de Grenoble · FRChurchill Hospital · GBCity of Hope · USCopenhagen University Hospital · DKFox Chase Cancer Center · USGerman Cancer Research Center · DEGhent University · BE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
GYNECOLOGIC ONCOLOGY GROUP HEADQUARTERSU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 1985 to 2013
$132.6M
Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
GYNECOLOGIC ONCOLOGY GROUP STATISTICAL OFFICEU10CA037517 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BLESSING, JOHN A · 1985 to 2013
$67.4M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Steven Allan Soper, Alan S Yu · 2019 to 2026
$21.5M
Cancer Research UK 10118Cancer Research UK 11174Cancer Research UK 20861Cancer Research UK 23382Cancer Research UK C1281/A12014Cancer Research UK C1287/A 10710Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C8197/A16565Medical Research Council MR/P012930/1NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001863NCI NIH HHS N02 CP011019NCI NIH HHS N02 CP065504NCI NIH HHS P20 CA233307NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA051008NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA125183NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA140323NCI NIH HHS R01 CA142996NCI NIH HHS R01 CA149429NCI NIH HHS R01 CA176785NCI NIH HHS R01 CA192393NCI NIH HHS R01 CA214545NCI NIH HHS R01 CA228198NCI NIH HHS R03 CA130065NCI NIH HHS R25 CA112486NCI NIH HHS RC4 CA153828NCI NIH HHS U01 CA116167NCI NIH HHS U01 CA161032NCI NIH HHS U10 CA027469NCI NIH HHS U10 CA037517NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS UM1 CA164920NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

backgroundHeight and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown.

methodsWe applied a Mendelian randomisation approach to examine height/BMI with ovarian cancer risk using the Consortium of Investigators for the Modifiers of BRCA1/2 (CIMBA) data set, comprising 14,676 BRCA1 and 7912 BRCA2 mutation carriers, with 2923 ovarian cancer cases. We created a height genetic score (height-GS) using 586 height-associated variants and a BMI genetic score (BMI-GS) using 93 BMI-associated variants. Associations were assessed using weighted Cox models.

resultsObserved height was not associated with ovarian cancer risk (hazard ratio [HR]: 1.07 per 10-cm increase in height, 95% confidence interval [CI]: 0.94-1.23). Height-GS showed similar results (HR = 1.02, 95% CI: 0.85-1.23). Higher BMI was significantly associated with increased risk in premenopausal women with HR = 1.25 (95% CI: 1.06-1.48) and HR = 1.59 (95% CI: 1.08-2.33) per 5-kg/m

conclusionOur observation of a positive association between BMI and ovarian cancer risk in premenopausal BRCA1/2 mutation carriers is consistent with findings in the general population.

Indexed as

Body HeightBody Mass IndexGenes, BRCA1Genes, BRCA2HeterozygoteMendelian Randomization AnalysisMutationAdultAgedFemaleHumansMenopauseMiddle AgedOvarian NeoplasmsProportional Hazards Models

Identifiers

PMID31213659
PMCPMC6738050
OpenAlexW2952644236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.